Clinical profiles and antimicrobial resistance patterns of invasive *Salmonella* infections in children in China

Wen Song¹,² · Qingwen Shan³ · Yue Qiu⁴ · Xianyao Lin¹ · Chunhui Zhu⁵ · Zhiqiang Zhuo⁶ · Caihong Wang⁶ · Jianning Tong⁷ · Rui Li⁷ · Chaomin Wan⁸ · Yu Zhu⁸ · Minxia Chen⁹ · Yi Xu⁹ · Dajiong Lin¹⁰ · Shouye Wu¹⁰ · Chunmei Jia¹¹ · Huiling Gao¹¹ · Junwen Yang¹² · Shiyong Zhao¹ · Mei Zeng⁴ · Collaborative Working Group of the Pediatric Subgroup of the China Society of Infectious Diseases

Received: 12 March 2022 / Accepted: 18 July 2022 / Published online: 30 August 2022
© The Author(s) 2022

Abstract
Invasive *Salmonella* infections result in a significant burden of disease including morbidity, mortality, and financial cost in many countries. Besides typhoid fever, the clinical impact of non-typhoid *Salmonella* infections is increasingly recognized with the improvement of laboratory detection capacity and techniques. A retrospective multicenter study was conducted to analyze the clinical profiles and antimicrobial resistance patterns of invasive *Salmonella* infections in hospitalized children in China during 2016–2018. A total of 130 children with invasive *Salmonella* infections were included with the median age of 12 months (range: 1–144 months). Seventy-nine percent of cases occurred between May and October. Pneumonia was the most common comorbidity in 33 (25.4%) patients. Meningitis and septic arthritis caused by nontyphoidal *Salmonella* (NTS) infections occurred in 12 (9.2%) patients and 5 (3.8%) patients. Patients <12 months (OR: 16.04) and with septic shock (OR: 23.4), vomit (OR: 13.33), convulsion (OR: 15.86), C-reactive protein (CRP) ≥40 g/L (OR: 5.56), and a higher level of procalcitonin (PCT) (OR: 1.05) on admission were statistically associated to an increased risk of developing meningitis. Compared to 114 patients with NTS infections, 16 patients with typhoid fever presented with higher levels of CRP and PCT (P < 0.05). The rates of resistance to ampicillin, sulfamethoxazole/trimethoprim, ciprofloxacin, and ceftriaxone among *Salmonella* Typhi and NTS isolates were 50% vs 57.3%, 9.1% vs 24.8%, 0% vs 11.2%, and 0% vs 9.9%, respectively. NTS has been the major cause of invasive *Salmonella* infections in Chinese children and can result in severe diseases. Antimicrobial resistance among NTS was more common.

Keywords Invasive nontyphoidal *Salmonella* · Typhoid fever · Children · China

Introduction
Typhoid fever and other invasive salmonellosis continue to cause an estimated 14.8 million cases and > 200,000 deaths annually, largely affecting children in low- and middle-income countries [1]. Enteric fever, the collective term for typhoid and paratyphoid fevers, describes a systemic infection caused by *Salmonella enterica* serovar Typhi or Paratyphi A, B, or C [2]. Nontyphoidal *Salmonella* (NTS) serovars that typically cause self-limiting diarrhea can also cause invasive systemic infections [3]. Nowadays, invasive NTS infections, which cause an estimated 535,000 cases and > 77,000 deaths annually, are increasingly becoming an important public health threat in low- and middle-income countries, and have gained greater recognition as an important disease in children younger than 5 years [1, 4]. A global systematic review and meta-analysis showed that the pooled case-fatality ratio (CFR) was 17.1% in Africa, 14.0% in Asia, 9.9% in Europe, and 9.6% in the Americas [5]. In some Asian countries such as India [6], Thailand [7], and Vietnam [8], enteric fever remains a public health issue. In China, the average incidence of typhoid and paratyphoid was 1.03/100 000 during 2009–2013 and decreased markedly...
over year [9]. However, foodborne NTS gastroenteritis and outbreaks increasingly gained public attention and an estimated 70–80% of bacterial food poisoning is caused by Salmonella [10, 11]. A recent study focused on the molecular epidemiology and antimicrobial resistance of invasive Salmonella strains in China [12]. However, few studies have been designed to comprehensively describe the case series of invasive NTS disease from different regions of China. Therefore, we conducted a retrospective multicenter study to recognize the detailed clinical profiles of invasive Salmonella infections in Chinese children.

Methods

Participating hospitals and sites

Ten tertiary hospitals from different provinces in China participated in this study during 2016–2018: four hospitals are located in the Southeast or East of China (Hangzhou Children’s Hospital, Jiangxi Provincial Children’s Hospital, Xiamen Children’s Hospital, and Qingdao Women and Children’s Hospital), four hospitals are located in the Southwest or South region (West China Women’s and Children’s Hospital, The First Affiliated Hospital of Guangxi Medical University, Guangzhou Women and Children’s Medical Center, and Hainan Women and Children’s Medical Center), one hospital is located in the north region (The Forth Hospital of Baotou), and the other one hospital is located in the central China (Henan Children’s Hospital).

Case definition

A case of invasive Salmonella infections is defined as a patient with symptoms consistent with an invasive bacterial infection, from whom culturing of a blood and/or other sterile body fluid (such as cerebrospinal fluid, pleural fluid, pericardial fluid, joint fluid, bone aspirate, or a deep tissue abscess) samples grew Salmonella Typhi, or Salmonella Paratyphi A, B, and C, or NTS serovar [13]. A case of meningitis is defined as a patient with clinical symptoms with leukocytosis of cerebrospinal fluid and a positive culture of cerebrospinal fluid culture and/or blood. A case of septic arthritis is defined as a patient with clinical symptoms such as swelling, redness, heat, and pain in a single joint associated with a decreased ability to move the joint and a positive culture of blood and/or synovial fluid.

Data collection and definition of disease outcomes

Hospitalized pediatric patients < 18 years of age who had invasive Salmonella disease infections and whose medical records were available for complete review were included in this study, based on microbiology registries in departments of laboratory medicine. Two designated clinical investigators at each participating hospital reviewed the medical records case-by-case. A standard case report form was used to record sites of bacteria isolation, patient’s demographics, clinical symptoms, laboratory findings, and disease outcomes. The final outcomes were evaluated based on the discharge records and were classified as follows: (1) recovery or improvement, (2) death or hopeless discharge, (3) transfer to another hospital under either parents’ request or doctors’ counsel (but not expected to die). Outcome 2 was considered to be fatal. Cases classified as “transfer to another hospital” were considered missing data because the final outcomes could not be determined.

Isolate identification and antimicrobial susceptibility testing

The clinical samples were processed following standard blood culture procedures. Species identification and antimicrobial susceptibility testing were performed at local hospital laboratories by automated systems such as Vitek or Phoenix, according to the Clinical and Laboratory Standards Institute (CLSI) performance guideline. Antimicrobial susceptibility testing was performed using minimum inhibitory concentrations (MICs) or the Kirby-Bauer disk diffusion method. The original results were interpreted according to the breakpoints of the CLSI standards [14]. The isolates were classified as resistant, intermediate, and sensitive. Isolates displaying intermediate susceptibility were not categorized as resistant in this study. Isolates resistant to three or more classes of antimicrobial agents were defined as multidrug resistant (MDR) [15].

Statistical analysis

Age groups were stratified as < 12 months of age and ≥ 12 months of age. Statistical analysis was performed using the SPSS Software (version 23.0 for windows; SPSS Inc., Chicago, IL, USA). For continuous variables, non-normally distributed variables were presented as medians and interquartile ranges (IQRs) and were compared by means of the Mann–Whitney non-parametric test. Categorical variables were expressed as percentages and compared by means of Fisher’s exact test or the chi-square test, as appropriate. The univariate analysis to compare between the meningitis group and non-meninigitis group was performed by binary logistic regression and the odds ratios (ORs) with 95% confidence intervals (CIs) were reported. Statistical significance was accepted at \( P \leq 0.05 \).
Results

The demographic and clinical features of the children with invasive Salmonella infections

In total, 130 children with invasive Salmonella infections were included in the study. Of these patients, 119 (91.5%) had cultures recovered from blood alone, 5 (3.8%) from cerebrospinal fluid alone, 4 (3.1%) from both blood and cerebrospinal fluid, 1 (0.8%) from joint fluid, and 1 (0.8%) from bone aspirate. The most cases were from Jiangxi Provincial Children’s Hospital (44), followed by Henan Children’s Hospital (35), West China Women’s and Children’s Hospital (14), Xiamen Children’s Hospital (9), Hainan Women and Children’s Medical Center (9), The First Affiliated Hospital of Guangxi Medical University (7), Guangzhou Women and Children’s Medical Center (5), Hangzhou Children’s Hospital (4), Qingdao Women and Children’s Hospital (2), and The Forth Hospital of Baotou (1). Seventy-seven (59.2%) patients were males. Median age was 12 (IQR: 8–20.25, range: 1–144) months; 85.4% were younger than 36 months old. Seventy-nine percent of cases occurred between May and October (see Fig. 1).

Among the 130 patients, the three most common clinical symptoms were fever with body temperature ≥38°C (118/130, 90.8%), diarrhea (43/130, 33.1%), and cough (37/130, 28.5%); 80.5% of febrile patients had maximum body temperature ≥39°C for 5 days of median duration (IQR 2–7 days, range: 1–90 days) prior to hospital admission.

Twelve (9.2%) patients (median age: 4 months) had meningitis and 5 (3.8%) patients (median age: 19 months) had septic arthritis, for whom NTS serovars (5/5) were the causative pathogens. Six patients with meningitis had comorbidity of pneumonia (4/6), cardiac disease (1/6), and hematological malignancies (2/6). Patients with arthritis had no comorbidity. As shown in Table 1, we found that the patients with meningitis were younger (P < 0.001) and had longer length of hospital stay (P = 0.025) than those without meningitis. In addition, according to the clinical symptoms, septic shock (P = 0.022), vomit (P = 0.001), and convulsion (P < 0.001) were significantly associated with meningitis caused by Salmonella infection. Also, the analysis of laboratory findings showed that the levels of C-reactive protein (CRP) ≥40 g/L (P = 0.012) and evaluated procalcitonin (PCT) (P < 0.001) were more common among the patients with meningitis. According to the univariate analysis, the risk factors of meningitis were patients <12 months of age (OR: 16.04, P = 0.009), septic shock (OR: 23.4, P = 0.013), vomit (OR: 13.33, P < 0.001), convulsion (OR: 15.86, P < 0.001), CRP ≥40 g/L (OR: 5.56, P = 0.009), and higher PCT (OR: 1.05, P = 0.013) (see Table 2).

The median length of hospital stay was 10 (IQR: 7–15.25, range: 1–80) days. Nine (6.9%) children were admitted to pediatric intensive care. One hundred and thirteen (86.9%) cases recovered or improved, 5 (3.8%) cases were deceased or hopeless discharged, and 12 (9.2%) cases were transferred to a different hospital or left against medical advice. The patients’ accompanying comorbidities included pneumonia (33/130, 25.4%), liver disease (9/130, 6.9%), cardiac disease (4/130, 3.1%), hematological malignancies (7/130, 5.4%), prematurity (3/130, 2.3%), congenital malformations (2/130, 1.5%), nephrotic syndrome (1/130, 0.8%), traumatic injury (1/130, 0.8%), and acute suppurative appendicitis with
perforation (1/130, 0.8%). Thirty-nine (30%) patients had more than one comorbidity.

The initial empirical antibiotic therapy included 3rd-generation cephalosporins or in combination with β-lactam (ceftriaxone, ceftizidime, ceftizoxime, cefoperazone-sulbactam) in 70 (53.8%) patients, penicillins or in combination with β-lactam (mezlocillin, mezlocillin-sulbactam) in 31 (23.8%) patients, 1st- or 2nd-generation cephalosporins in 11 (8.5%) patients, carbapenems in 10 (7.7%) patients, macrolides in 7 (5.4%) patients, and aztreonam in 1 (0.8%) patient. Some

| Parameters | Total | Meningitis group | Non-meningitis group | P value |
|------------|-------|------------------|----------------------|---------|
| Age (month), median (IQR) | 12 (8–20.25) | 4 (1–8) | 12 (9–21) | <0.001* |
| Gender, male (%) | 77 (59.2) | 7 (58.3) | 70 (59.3) | 1.000 |
| Comorbidities (%) | 55 (42.3) | 6 (50.0) | 49 (41.5) | 0.571 |
| Length (days) of hospital stay, median (IQR) | 10 (7–15.25) | 28.5 (8.75–30.75) | 10 (6.75–14) | 0.025* |

**Symptoms on admission**

- Fever (%) | 118 (90.8) | 12 (100) | 106 (89.8) | 0.602 |
- Fever duration (day), median (IQR) | 5 (2–7) | 3 (1.25–5.75) | 5 (2–7) | 0.116 |
- Septic shock (%) | 3 (2.3) | 1 (0.8) | 15 (12.7) | 0.358 |
- Rash (%) | 15 (11.5) | 0 (0) | 5 (4.17) | 0.177 |
- Cough (%) | 37 (28.5) | 1 (8.3) | 36 (30.5) | 0.389 |
- Respiratory distress (%) | 5 (3.8) | 1 (8.3) | 4 (3.4) | 1.000 |
- Tachypnea (%) | 8 (6.2) | 0 (0) | 8 (6.8) | 0.022* |
- Cyanosis (%) | 2 (1.5) | 1 (8.3) | 1 (0.8) | 0.011* |
- Vomit (%) | 11 (8.5) | 5 (41.7) | 6 (5.1) | 0.001* |
- Diarrhea (%) | 43 (33.1) | 1 (8.3) | 42 (35.6) | 0.103 |
- Convulsion (%) | 13 (10) | 6 (50) | 7 (5.9) | <0.001* |

**Laboratory indicators on admission**

- Leukocyte <4000 or >15,000 count/mm³ (%) | 43(35) | 6(50) | 37(33.3) | 0.340 |
- Neutropenia (%) | 8 (6.5) | 0 (0) | 8 (7.2) | 1.000 |
- Platelet <100,000 count/mm³ (%) | 12 (9.8) | 1 (8.3) | 11 (9.9) | 0.001* |
- CRP ≥40 g/L (%) | 35 (30.7) | 8 (66.7) | 27 (26.5) | 0.012* |
- PCT (µg/L), median(IQR) | 0.37 (0.14–2.08) | 19.11 (1.97–42.31) | 0.3 (0.13–1.56) | <0.001* |
- GPT >40 U/L (%) | 44 (47.3) | 6 (60) | 38 (45.8) | 0.509 |
- GOT >40 U/L (%) | 62 (66.7) | 5 (50) | 57 (68.7) | 0.292 |

CRP, C-reactive protein; PCT, procalcitonin; GPT, glutamic-pyruvic transaminase; GOT, glutamic-oxaloacetic transaminase

*P < 0.05

**Table 2** Risk factors for children with meningitis caused by *Salmonella* infection. Univariate analysis

| Variables | Meningitis group | Non-meningitis group | OR (95%CI) | P value |
|-----------|------------------|----------------------|------------|---------|
| Age <12 months | 11 (91.7) | 48 (40.7) | 16.04 (2–128.38) | 0.009* |
| Septic shock | 2 (16.7) | 1 (0.8) | 23.4 (1.95–281.05) | 0.013* |
| Vomit | 5 (41.7) | 6 (5.1) | 13.33 (3.25–54.68) | <0.001* |
| Convulsion | 6 (50) | 7 (5.9) | 15.86 (4.05–62.11) | <0.001* |
| CRP ≥40 g/L | 8 (66.7) | 27 (26.5) | 5.56 (1.55–19.95) | 0.009* |
| PCT (µg/L) | 19.11 (1.97–42.31) | 0.3 (0.13–1.56) | 1.05 (1.01–1.1) | 0.013* |

*P < 0.05

European Journal of Clinical Microbiology & Infectious Diseases (2022) 41:1215–1225
patients were given more than one antibiotic (3rd-generation cephalosporin-based, in combination with macrolides or vancomycin or linezolid). Of those receiving initial penicillins or in combination with β-lactam, and 1st- or 2nd-generation cephalosporins, 17 were switched to 3rd-generation cephalosporins or carbapenems.

Serovar distribution of invasive Salmonella infections

The distribution of all the invasive Salmonella serovars is displayed in Table 3. All of the 5 Salmonella Paratyphi isolates were from Hainan Women and Children’s Medical Center in the south and 54.5% (6/11) of Salmonella Typhi isolates were from the First Affiliated Hospital of Guangxi Medical University in the south. The clinical characteristics of invasive Salmonella infections stratified by serovars are shown in Table 4. The patients with invasive NTS infections were younger than those with invasive Salmonella Typhi and Salmonella Paratyphi infections (P = 0.001). Moreover, the presence of comorbidities was significantly higher among those with invasive Salmonella Typhi and Salmonella Paratyphi infections (P = 0.005). There was no statistical difference in clinical symptoms on admission between the two groups. Patients with Salmonella Typhi and Salmonella Paratyphi infections had the higher frequencies of CRP ≥ 40 g/L (P = 0.003) and platelet < 100,000 count/mm³ (P = 0.040) as well as the higher PCT (P = 0.013), compared to the NTS group.

All of the 11 Salmonella Typhi isolates were recovered from the blood. One Salmonella Paratyphi isolate was recovered from cerebrospinal fluid and the other 4 Salmonella Paratyphi isolates were recovered from the blood. Eight isolates from cerebrospinal fluid were NTS including one Salmonella enteritidis serovar, one group E serovar, and six other serovars. The isolate from joint fluid was Salmonella enteritidis and the isolate from bone aspirate was other NTS serovars (Table 5).

Antimicrobial resistance of invasive Salmonella isolates

A total of 127 Salmonella isolates were tested for antimicrobial susceptibility. The resistance patterns of invasive Salmonella isolates to antimicrobial agents are shown in Table 6. There were 50% of the Salmonella Typhi isolates resistant to ampicillin or piperacillin, followed by ampicillin/sulbactam (20%), chloramphenicol (20%), sulfamethoxazole/trimethoprim (9.1%), and cefepime (9.1%). However, the NTS serovars had high rates of resistance to ampicillin (57.3%), ampicillin/sulbactam (54.7%), piperacillin (45.3%), and tetracycline (32%). All of the Salmonella Typhi, Salmonella Paratyphi, and NTS serovars were susceptible to tested carbapenems (such as imipenem, meropenem, or ertapenem). Furthermore, we detected that the Salmonella Paratyphi isolates exhibited high rates of resistance to ciprofloxacin (66.7%) and ampicillin (40%). In total, 26 (20.5%) isolates were MDR. There was no MDR detected in the Salmonella Typhi group. The MDR rates of Salmonella Paratyphi and NTS serovars were 20% and 22.5%, respectively (see Table 6).

Discussion

This study is meaningful not only for its clinical purpose but also for its regional distribution in China. The clinical data from the 10 hospitals located in different regions during a certain period from 2016 to 2018 reliably represent the major demographic and clinical characteristics of children who suffered from invasive salmonellosis in China. Obviously, NTS other than Salmonella Typhi or Salmonella Paratyphi has been the major cause of invasive Salmonella infections in Chinese children. The national prevalence of typhoid and paratyphoid in China declined with year since 2008[9]. We also found that invasive typhoid and paratyphoid in this case cohort were mostly from Hainan province and Guangxi province, which is characteristic of warm and humid tropical climate with economy and culture relatively underdeveloped. Besides, the prevalence of antimicrobial resistance among NTS was higher than among Salmonella Typhi or Paratyphi. The data of antimicrobial resistance will be useful to help guide the appropriate use of empirical antibiotics and improve the clinical outcome.

The majority of NTS infections occurred between May and October. The seasonal trend is consistent to that of NTS gastroenteritis reported by national laboratory surveillance network [10, 16]. Seasonal variation was reported in other countries. In Mali, invasive NTS infection appeared most frequently from August to November and peaked in October, toward the middle and end of the rainy season [13]. In Malaysian Borneo, no significant correlation was observed in invasive Salmonella infection among children between the monthly incidence and average monthly rainfall [17].

We observed that 85.4% of cases occurred in children younger than 36 months old with the median age of 12 months. Meanwhile, we also noticed that children suffering from invasive NTS disease are younger than those suffering from non-invasive NTS gastroenteritis in Chinese children (the median age: 18 months) [18]. Generally, the age distribution of case series in Chinese children is similar to that reported in other developed and developing countries. In Africa, infants aged 6–11 months and toddlers aged 12–23 months exhibit the highest incidence of severe invasive NTS disease [19]. An Australian study also showed that age-related peaks in NTS infections were seen in infants,
Table 3: The surveillance cohort of invasive *Salmonella* infections stratified by *Salmonella enterica* serovars

| Serovar          | No. of cases | Jiangxi Provincial Children’s Hospital, no | Henan Children’s Hospital, no | West China Women’s and Children’s Hospital, no | Xiamen Children’s Hospital, no | Hainan Women and Children’s Medical Center, no | The First Affiliated Hospital of Guangxi Medical University, no | Guangzhou Women and Children’s Hospital, no | Hangzhou Children’s Hospital, no | Qingdao Women and Children’s Hospital, no | The Forth Hospital of Baotou, no |
|------------------|--------------|---------------------------------------------|-------------------------------|-----------------------------------------------|--------------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------------|---------------------------------|-----------------------------------|-----------------------------------|
| S. Typhi         | 11           | 2                                           | 0                             | 1                                             | 0                             | 0                                             | 6                                             | 1                                      | 1                               | 0                                 | 0                                 |
| S. Paratyphi     | 5            | 0                                           | 0                             | 0                                             | 5                             | 0                                             | 0                                             | 0                                      | 0                               | 0                                 | 0                                 |
| NTS              |              |                                             |                               |                                               |                               |                                               |                                               |                                        |                                  |                                   |                                   |
| Group B          | 10           | 0                                           | 0                             | 3                                             | 3                             | 0                                             | 0                                             | 1                                      | 2                               | 1                                 | 0                                 |
| Derby            | 2            | 0                                           | 0                             | 1                                             | 0                             | 0                                             | 0                                             | 1                                      | 0                               | 0                                 | 0                                 |
| Typhimurium      | 3            | 0                                           | 0                             | 1                                             | 1                             | 0                                             | 0                                             | 1                                      | 0                               | 0                                 | 0                                 |
| Group C          | 8            | 2                                           | 3                             | 1                                             | 2                             | 0                                             | 0                                             | 0                                      | 0                               | 0                                 | 0                                 |
| Choleraesuis     | 5            | 2                                           | 3                             | 0                                             | 0                             | 0                                             | 0                                             | 0                                      | 0                               | 0                                 | 0                                 |
| Group D          | 11           | 0                                           | 0                             | 6                                             | 0                             | 1                                             | 0                                             | 3                                      | 0                               | 1                                 | 0                                 |
| Enteritidis      | 7            | 0                                           | 0                             | 3                                             | 0                             | 1                                             | 0                                             | 2                                      | 0                               | 1                                 | 0                                 |
| Dublin           | 4            | 0                                           | 0                             | 3                                             | 0                             | 0                                             | 0                                             | 1                                      | 0                               | 0                                 | 0                                 |
| Group E          | 3            | 0                                           | 0                             | 0                                             | 3                             | 0                                             | 0                                             | 0                                      | 0                               | 0                                 | 0                                 |
| Meleagridis      | 1            | 0                                           | 0                             | 0                                             | 1                             | 0                                             | 0                                             | 0                                      | 0                               | 0                                 | 0                                 |
| Other serovars   | 82           | 40                                          | 32                            | 3                                             | 3                             | 1                                             | 1                                             | 0                                      | 1                               | 0                                 | 1                                 |

*S. Typhi, Salmonella Typhi; S. Paratyphi, Salmonella Paratyphi; NTS, nontyphoidal Salmonella*
which was likely to be due to highly susceptible intestinal microflora in the setting of an immature immune system [20]. Thus, anti-infective therapy should be empirically initiated for young children who are at high risk of developing invasive salmonellosis.

Only 33% of cases presented with gastroenteritis, and even 9.2% of cases were afebrile. Of note, pneumonia was the common accompanying comorbidity in children with invasive salmonellosis. Most of African children with invasive NTS disease were reported to present with respiratory symptoms [21, 22]. In Ghana, NTS was shown to be the predominant organism isolated in children with clinical pneumonia [23]. In Malaysian Borneo, pneumonia was the primary presentation, seen in 76% of children with Salmonella enteritis bacteremia [17]. In Thailand, clinical pneumonia was diagnosed in 25% of children with invasive NTS disease [24]. Taken together, the manifestation of invasive salmonella infection was nonspecific. Besides, we noticed 9.2% of cases were complicated with serious meningitis and arthritis. Infants were much more likely to develop meningitis compared to children ≥12 months of age. In addition to young age, the presentations of septic shock, vomit, convulsion, CRP ≥40 g/L, and higher level of PCT on admission were statistically related to an increased risk of developing meningitis. These warning parameters will help clinical decision on how to proceed the management and investigation of suspected Salmonella infection in a timely manner. In regions with a high prevalence of invasive NTS infection, Salmonella has been reported to be the leading cause of septic arthritis in children [25]. In this current study, septic arthritis secondary to NTS infection was not common and seen in 3.8%
of patients. However, NTS should not be neglected as a pathogen of septic arthritis among young children.

In this survey, the patients in the NTS group were younger than those in the *Salmonella* Typhi and *Salmonella* Paratyphi group (*P* = 0.001). The presence of comorbidities was clearly higher among those infected by *Salmonella* Typhi and *Salmonella* Paratyphi (*P* = 0.005). But there was not any statistical significance between the two groups regarding gender or symptoms on admission such as fever, septic shock, rash, cough, respiratory distress, tachypnea, cyanosis, vomit, diarrhea, and convulsion. Although the clinical manifestations appeared to be nonspecific, some meaningful laboratory factors were discovered in the *Salmonella* Typhi and *Salmonella* Paratyphi group such as the presence

| Table 5 The distribution of *Salmonella enterica* serovars stratified by the sites of invasive *Salmonella* infections |
|-----------------------------------------------|
| Blood, n (% of N) | Cerebrospinal fluid, n (% of N) | Joint fluid, n (% of N) | Bone aspirate, n (% of N) |
|-------------------|---------------------------------|------------------------|-------------------------|
| Total number, N   | 119 (100)                       | 9 (100)                | 1 (100)                 | 1 (100)                 |
| S. Typhi          | 11 (9.2)                        | 0 (0)                  | 0 (0)                   | 0 (0)                   |
| S. Paratyphi      | 4 (3.4)                         | 1 (11.1)               | 0 (0)                   | 0 (0)                   |
| NTS               | 104 (87.4)                      | 8 (88.9)               | 1 (100)                 | 1 (100)                 |
| Group B           | 10 (8.4)                        | 0 (0)                  | 0 (0)                   | 0 (0)                   |
| Derby             | 2 (1.7)                         | 0 (0)                  | 0 (0)                   | 0 (0)                   |
| Typhimurium       | 3 (2.5)                         | 0 (0)                  | 0 (0)                   | 0 (0)                   |
| Group C           | 8 (6.7)                         | 0 (0)                  | 0 (0)                   | 0 (0)                   |
| Choleraesuis      | 5 (4.2)                         | 0 (0)                  | 0 (0)                   | 0 (0)                   |
| Group D           | 9 (7.6)                         | 1 (11.1)               | 1 (100)                 | 0 (0)                   |
| Enteritidis       | 5 (4.2)                         | 1 (11.1)               | 1 (100)                 | 0 (0)                   |
| Dublin            | 4 (3.4)                         | 0 (0)                  | 0 (0)                   | 0 (0)                   |
| Group E           | 2 (1.7)                         | 1 (11.1)               | 0 (0)                   | 0 (0)                   |
| Meleagridis       | 1 (0.8)                         | 0 (0)                  | 0 (0)                   | 0 (0)                   |
| Other serovars    | 75 (63)                         | 6 (66.7)               | 0 (0)                   | 1 (100)                 |

| Table 6 Resistance patterns of invasive *Salmonella* isolates to antimicrobial agents |
|-----------------------------------------------|
| Antimicrobial drugs | Percentage resistance % (number of isolates resistant/number of isolates tested) |
|---------------------|----------------------------------------------------------------------------------|
|                     | *Salmonella Typhi* | *Salmonella Paratyphi* | Nontyphoidal *Salmonella* |
|---------------------|--------------------|------------------------|--------------------------|
| Ampicillin          | 50 (5/10)          | 40 (2/5)               | 57.3 (63/110)            |
| Piperacillin        | 50 (4/8)           | NT                     | 45.3 (29/64)             |
| Ampicillin/sulbactam| 20 (1/5)           | NT                     | 54.7 (58/106)            |
| Piperacillin/tazobactam| 0 (0/11)   | NT                     | 2.8 (3/106)              |
| Cefotaxime or ceftriaxone | 0 (0/11) | 20 (1/5)               | 9.9 (11/111)             |
| Ceftazidime         | 0 (0/10)           | 20 (1/5)               | 7.2 (8/111)              |
| Cefepime            | 9.1 (1/11)         | 0 (0/5)                | 5.5 (6/110)              |
| Aztreonam           | 0 (0/11)           | NT                     | 7.3 (8/109)              |
| Gentamicin or tobramycin | 0 (0/5)    | NT                     | 18.5 (20/108)            |
| Amikacin            | 0 (0/5)            | NT                     | 10.5 (11/105)            |
| Imipenem            | 0 (0/11)           | NT                     | 0 (0/108)                |
| Meropenem           | 0 (0/8)            | NT                     | 0 (0/88)                 |
| Ertapenem           | 0 (0/2)            | 0 (0/5)                | 0 (0/32)                 |
| Tetracycline        | 0 (0/2)            | NT                     | 32 (24/75)               |
| Ciprofloxacin or levofloxacin | 0 (0/9) | 66.7 (2/3)             | 11.2 (11/98)             |
| Sulfamethoxazole/trimethoprim | 9.1 (1/11) | 20 (1/5)               | 24.8 (27/109)            |
| Chloramphenicol     | 20 (1/5)           | NT                     | 16 (12/75)               |
| MDR                 | 0 (0/11)           | 20 (1/5)               | 22.5 (25/111)            |

*NT*, not test; *MDR*, multidrug resistance
of CRP ≥ 40 g/L (P = 0.003) and platelet < 100,000 count/mm³ (P = 0.04) as well as higher PCT (P = 0.013) compared to the NTS group. Because of the insufficient samples in the fatal group, we could not step to perform the multivariable analysis and this remains a limitation of our study. Although the reported case-fatality rate of invasive NTS infections in Mali and Vietnam was as high as 20.3 to 26% [8, 19], the clinical outcome is better in Chinese children with about 4% of case-fatality rate. The better outcome in Chinese children is attributable to timely empirical antibiotic initiation in the hospital, as well as less immunocompromised children in this case series.

When choosing empiric treatment, the local prevalence of antimicrobial resistance should be considered. Currently, MDR Salmonella Typhi is considered endemic in many developing countries, especially in areas of South and Southeast Asia, even in the Netherlands [26]. However, we found no MDR in the Salmonella Typhi group. Chloramphenicol, ampicillin, and sulfamethoxazole-trimoxazole had ever been the first-line antibiotics for the treatment of salmonellosis since the 1970s, but fell in disuse because of resistance or toxicity concerns. So far, ampicillin resistance remains at the high level in many developing countries [19, 27, 28], but at the low level in some developed countries, for example, in Australia and England, where the prevalence of ampicillin was reported at 9.9% and 17.3% [16, 20]. In this current study, the prevalence of ampicillin and ampicillin/subbactam resistance among Salmonella isolates remained high, similar to the previous studies from China [18, 29, 30]. For children, the third-generation cephalosporins are the preferred choice for the treatment of typhoid fever and severe NTS infections [31]. However, we noticed that 20% of Salmonella Paratyphi isolates and 9.9% of the NTS isolates displayed resistance to cefotaxime or ceftriaxone, which is similar to the situation reported in Kenya [32]. In other countries such as England, Vietnam, and the USA, the Salmonella resistance is at the low level with the reported prevalence of 0.9 to 3% [16, 27, 33]. Ciprofloxacin is also recommended as the first-line regimen for the treatment of enteric fever and severe NTS infection by the WHO [31]. However, there is an increasing trend of fluoroquinolone resistance in many areas, mostly in Asia [34]. In the current study, the resistances to ciprofloxacin in the Salmonella Typhi, Salmonella Paratyphi, and NTS isolates were 0, 66.7%, and 11.2%, respectively. In a study conducted in Shanghai, 61.8% of NTS isolates showed decreased ciprofloxacin susceptibility [12]. Similarly, increasing ciprofloxacin resistance was observed from 2012 to 2017 (4.2 to 22.0%) in Zimbabwe [35]. In European countries, the proportion of Salmonella isolates resistant to ciprofloxacin significantly increased to 12.5% in 2018 [36]. NTS resistance rate in NTS blood isolates in the UK was up to 20.7% [16]. The percentage of Salmonella Typhi nonsusceptible to ciprofloxacin reached 74% but NTS resistance percentage in NTS was only 7% in 2017 in the USA [33]. These data might be helpful for us to choose empirical antibiotics according to different serovars and patient location in clinical practice. Salmonellosis is now a common disease for travelers.

Although this multicenter study reported a pooled case series, it still has a few limitations. Firstly, some NTS isolates were unclassified as well as some clinical data was missing. Secondly, we notice the potential bias of regional case distribution owing to some clinical factors, especially overuse broad-spectrum antibiotics for febrile children prior to hospitalization with no blood culture testing. Even so, we still feel that inclusion of a few cases from these hospitals can at least reflect the current real clinical picture of invasive Salmonella infections in China. Thirdly, due to the retrospective study limitation, we could not obtain the isolates from the different hospitals to perform laboratory-based measurement. However, we adjusted the MIC data of isolates according to the Clinical and Laboratory Standards Institute (CLSI) performance guideline and re-affirmed the original results of antimicrobial susceptibility testing. Fourthly, antimicrobial susceptibility to azithromycin was not evaluated in all participating hospitals, which is recommended as the first choice for the treatment of enteric fever and invasive NTS-associated diarrhea [31]. Notwithstanding these limitations in this retrospective study, our findings provide a comprehensive description to date of clinical characteristics and antimicrobial susceptibility of pediatric invasive Salmonella infection from ten provinces across China. For invasive salmonellosis, as an important clinical and public health issue, continued surveillance should be performed.

Acknowledgements We thank the members of the Collaborative Working Group of Pediatric Subgroups of China Society of Infectious Diseases for collecting the data for this study.

Declarations

Ethics approval This study was reviewed and approved by the Ethics Committee of Fudan Children’s Hospital. Informed consent from patients was not required by the Ethics Committee, because there was no contact with patients and all data were deidentified.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will

 Springer
need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Duff N, Steele AD, Garrett D (2020) Global Action for Local Impact: the 11th international conference on typhoid and other invasive salmonelloses. Clin Infect Dis 71(Supplement_2):S59–S63
2. Carey ME, MacWright WR, Im J, Meiring JE, Gibani MM, Park SE et al (2020) The Surveillance for Enteric Fever in Asia Project (SEFA), Severe Typhoid Fever Surveillance in Africa (SETA), Surveillance of Enteric Fever in India (SEFI), and Strategic Typhoid Alliance Across Africa and Asia (STRA TAA) population-based enteric fever studies: a review of methodological similarities and differences. Clin Infect Dis 71(Supplement_2):S102–S10
3. Langridge GC, Nair S, Wain J (2009) Nontyphoidal Salmonella serovars cause different degrees of invasive disease globally. J Infect Dis 199(4):602–603
4. Kariuki S, Owusu-Dabo E (2020) Research on invasive non-typhoidal Salmonella disease and developments towards better understanding of epidemiology, management, and control strategies. Clin Infect Dis 71(Supplement_2):S127–S9
5. Marchello CS, Birkhold M, Crump JA (2022) Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis. Lancet Infect Dis 22(5):692–705
6. Menezes GA, Khan MA, Harish BN, Parija SC, Goessens W, Vidyalakshmi K et al (2010) Molecular characterization of antimicrobial resistance in non-typhoidal salmonellae associated with systemic manifestations from India. J Med Microbiol 59(Pt 12):1477–1483
7. Hendriksen RS, Hyytitia-Trees E, Pulsrikarn C, Pornruangwong S, Chaichana P, Svendsen CA et al (2012) Characterization of Salmonella enterica serovar Enteritidis isolates recovered from blood and stool specimens in Thailand. BMC Microbiol 12:92
8. Phu Huong Lan N, Le Thi Phuong T, Nguyen Huu H, Thuy L, Mather AE, Park SE et al (2016) Invasive non-typhoidal Salmonella infections in Asia: clinical observations, disease outcome and dominant serovars from an infectious disease hospital in Vietnam. PLoS Negl Trop Dis 10(8):e0004857
9. Cao Y, Han YY, Liu FF, Liao QH, Li J, Diao BW et al (2018) Epidemiological characteristics and molecular typing of typhoid and paratyphoid in China, 2009–2013. Zhonghua Liuxing Bing Xue Za Zhi 39(3):337–341
10. Li W, Pires SM, Liu Z, Ma X, Liang J, Jiang Y et al (2020) Surveillance of foodborne disease outbreaks in China, 2003–2017. Food Control 118
11. Zhan Z, Kuang D, Liao M, Zhang H, Lu J, Hu X et al (2017) Antimicrobial susceptibility and molecular typing of Salmonella Serftenberg isolated from humans and other sources in Shanghai, China, 2005 to 2011. J Food Prot 80(1):146–150
12. Zhan Z, Xu X, Gu Z, Meng J, Wufuer X, Wang M et al (2019) Molecular epidemiology and antimicrobial resistance of invasive non-typhoidal Salmonella in China, 2007–2016. Infect Drug Resist 12:2885–2897
13. Still WL, Tapia MD, Tennant SM, Sylla M, Toure A, Badji H et al (2020) Surveillance for invasive Salmonella disease in Bamako, Mali, from 2002 to 2018. Clin Infect Dis 71(Supplement_2):S130–S40
14. Qiu Y, Yang J, Chen Y, Yang J, Zhi Q, Zhu C et al (2020) Microbiological profiles and antimicrobial resistance patterns of pediatric bloodstream pathogens in China, 2016–2018. Eur J Clin Microbiol Infect Dis 40:739–749
15. Dong N, Li Y, Zhao J, Ma H, Wang J, Liang B et al (2020) The phenotypic and molecular characteristics of antimicrobial resistance of Salmonella enterica subsp. enterica serovar Typhimurium in Henan Province, China. BMC Infect Dis 20(1):511
16. Katoyo S, Muller-Pebody B, Minaji M, Powell D, Johnson AP, De Pinna E et al (2019) Epidemiology and outcomes of nontyphoidal Salmonella bacteremias from England, 2004 to 2015. J Clin Microbiol 57(1):e01189–18
17. Mohan A, Munusamy C, Tan YC, Muthuvelu S, Hashim R, Chien SL et al (2019) Invasive Salmonella infections among children in Bintulu, Sarawak, Malaysian Borneo: a 6-year retrospective review. BMC Infect Dis 19(1):330
18. Li Y, Xie X, Xu X, Wang X, Chang H, Wang C et al (2014) Nontyphoidal salmonella infection in children with acute gastroenteritis: prevalence, serotypes, and antimicrobial resistance in Shanghai. China Foodborne Pathog Dis 11(3):200–206
19. Tapia MD, Tennant SM, Bornstein K, Oowuchekwa U, Tamboura B, Maiga A et al (2015) Invasive nontyphoidal Salmonella infections among children in Mali, 2002–2014: microbiological and epidemiologic features guide vaccine development. Clin Infect Dis 61(Suppl 4):S532–S538
20. Wilson HL, Kennedy KJ, Moffatt CR (2018) Epidemiology of non-typhoidal Salmonella infection in the Australian Capital Territory over a 10-year period. Intern Med J 48(3):316–323
21. MacLennan CA, Msefula CL, Gondwe EN, Gilchrist JJ, Pensulo P, Mandala WL et al (2017) Presentation of life-threatening invasive nontyphoidal Salmonella disease in Malawian children: a prospective observational study. PLoS Negl Trop Dis 11(12):e0006027
22. Brett AJ, Oundo JO, Mwangi I, Ochola L, Lowe B, Berkley JA (2006) Salmonella bacteremia in Kenyan children. Pediatr Infect Dis J 25(3):230–236
23. Schwarz NG, Sarpong N, Hünger F, Marks F, Acquah SEK, Agyekum A et al (2010) Systemic bacteraemia in children presenting with clinical pneumonia and the impact of non-typhoid salmonella (NTS). BMC Infect Dis 10(1)
24. Punpanich W, Netsawang S, Thippated C (2012) Invasive salmonellosis in urban Thai children. Pediatr Infect Dis J 31(8):e105–e110
25. Lavy CBD (2006) Septic arthritis in Western and sub-Saharan African children - a review. Int Orthop 31(2):137–144
26. Mughini-Gras L, Pinjaeker R, Duijster J, Heck M, Wit B, Veldman K et al (2020) Changing epidemiology of invasive non-typhoid Salmonella infection: a nationwide population-based registry study. Clin Microbiol Infect 26(7):941 e9-e14
27. Parisi A, Phuong TLT, Mather AE, Jombart T, Tuyen HT, Lan NPH et al (2020) The role of animals as a source of antimicrobial resistant nontyphoidal Salmonella causing invasive and non-invasive human disease in Vietnam. Infect Genet Evol 85
28. Kariuki S, Mbae C, Van Puyvelde S, Onsare R, Kavai S, Wairimu C et al (2020) High relatedness of invasive multi-drug resistant non-typhoidal Salmonella genotypes among patients and asymptomatic carriers in endemic informal settlements in Kenya. PLoS Negl Trop Dis 14(8):e0008440
29. Wei Z, Xu X, Yan M, Chang H, Li Y, Kan B et al (2019) Salmonella Typhimurium and Salmonella Enteritidis infections in sporadic diarrhea in children: source tracing and resistance to third-generation cephalosporins and ciprofloxacin. Foodborne Pathog Dis 16(4):244–255
30. Lan R, Wu S, Gao Y, Zhang X, Feng Z, Wang Z et al (2011) Laboratory-based surveillance of nontyphoidal Salmonella infections in China. Foodborne Pathog Dis 8(8):921–927
31. Organization WH The WHO Essential Medicines List Antibiotic Book: improving antibiotic AWaReness. Geneva2021 [cited
2021. Available from: https://www.who.int/publications/m/item/the-who-essential-medicines-list-antibiotic-book-improving-antibiotic-awareness.

32. Muthumbi E, Morpeth SC, Ooko M, Mwanzu A, Mvarumba S, Mturi N et al (2015) Invasive salmonellosis in Kilifi. Kenya Clin Infect Dis 61(Suppl 4):S290–301

33. Prevention CfDCa (2019) Antibiotic resistance threats in the United States, 2019 [Available from: http://www.cdc.gov/drugresistance/biggest-threats.html.

34. Britto CD, Wong VK, Dougan G, Pollard AJ (2018) A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid. PLoS Negl Trop Dis 12(10):e0006779

35. Mashe T, Gudza-Mugabe M, Tarupiwa A, Munemo E, Mtupuriznyowera S, Smouse SL et al (2019) Laboratory characterisation of Salmonella enterica serotype Typhi isolates from Zimbabwe, 2009–2017. BMC Infect Dis 19(1):487

36. European Food Safety A, European Centre for Disease P, Control (2020) The European Union Summary Report on Antimicrobial Resistance in zoonotic and indicator bacteria from humans, animals and food in 2017/2018. EFSA J 18(3):e06007.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Wen Song1,2 · Qingwen Shan3 · Yue Qiu4 · Xianyao Lin1 · Chunhui Zhu5 · Zhiqiang Zhuo6 · Caihong Wang6 · Jianning Tong7 · Rui Li7 · Chaomin Wan8 · Yu Zhu8 · Minxia Chen9 · Yi Xu9 · Daojiong Lin10 · Shouye Wu10 · Chunmei Jia11 · Huiling Gao11 · Junwen Yang12 · Shiyong Zhao1 · Mei Zeng4 · Collaborative Working Group of the Pediatric Subgroup of the China Society of Infectious Diseases

1 Department of Infectious Diseases, Hangzhou Children’s Hospital, 195 Wenhui Road, Hangzhou 310014, China
2 Department of Hospital Infection Management, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, 261 Huaansha Road, Hangzhou 310006, China
3 Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
4 Department of Infectious Diseases, Children’s Hospital of Fudan University, 399 Wanyuan Road, Shanghai 201102, China
5 Department of Infectious Diseases, Jiangxi Provincial Children’s Hospital, Nanchang, China
6 Department of Infectious Diseases, Xiamen Children’s Hospital, Xiamen, China
7 Department of Pediatric, Gastroenterology and Infectious Diseases, Qingdao Women and Children’s Hospital, Qingdao, China
8 Department of Pediatrics, Sichuan University West China Second Hospital (West China Women’s and Children’s Hospital), Chengdu, China
9 Department of Infectious Diseases, Guangzhou Women and Children’s Medical Center, Guangzhou, China
10 Department of Infectious Diseases, Hainan Women and Children’s Medical Center, Haikou, China
11 Department of Pharmacy, The Forth Hospital of Baotou, Baotou, China
12 Department of Microbiology Laboratory, Children’s Hospital Affiliated to Zhengzhou University (Henan Children’s Hospital), Zhengzhou, China